A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of
oseltamivir. Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of
the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins
on the surface of platelets. By blocking the activity of the enzyme, oseltamivir may prevent
platelet destruction in liver.The project was undertaking by Qilu Hospital of Shandong
University and other 4 well-known hospitals in China. In order to report the efficacy and
safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of
immune thrombocytopenia (ITP) with high platelet desialylation level, compared to high-dose
dexamethasone therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Shandong University
Collaborators:
Anhui Medical University Shenzhen Second People's Hospital The Affiliated Hospital of the Chinese Academy of Military Medical Sciences The First Affiliated Hospital of Dalian Medical University Zhejiang Provincial Hospital of TCM